Background: Systemic Lupus Erythematosus (SLE) is a systemic inflammatory disease associated with genetic, environmental, hormonal and immunological factors. Vitamin D levels are nowadays considered as one possible factor associated with disease activity. Therefore, previous studies have analyzed vitamin D to the severity of SLE. Objectives: To assess the Vitamin D status in paraguayan SLE patients and its association with disease activity. Methods: An observational Trial has been performed on individuals diagnosed with SLE. Epidemiological, clinical and biochemical data have been recorded for each patient to study the association between vitamin D concentrations, the phospho-calcium metabolism parameters and disease activity. Quantitative determination of Vitamin D was perform using chemoluminescence ARCHITEC assay. Vitamin D status was interpreted as follows: deficiency ≤20 ng/ml and insufficiency 21-29 ng/ml. The statistical association tests were performed using linear (SLEDAI activity index) and logistic (Inactive/Mild vs Moderate/Severe) regressions. The epidemiological, clinical and biochemical variables were used as explanatory variables in these models.This study is a preliminary analysis of a trial supported by CONACYT (Paraguay) to investigate the role of vitamin D in patients diagnosed with SLE. Results: We included 77 SLE patients, of whom 94.8% (73/77) were female. The average age of patients at the time of the study was 30.7±10.3 years. All patients received calcium supplements associated with vitamin D. The average vitamin D concentration was 32.2±12.10 ng /ml. 29.9% (23/77) of patients had vitamin D insufficiency and 13.0% had vitamin D deficiency. 94.8% (73/77) of the population had normal serum calcium and the total population had a normal phosphoremia. As for the dosage of PTH, it was found that 27.3% (21/77) have high values of PTH. 20.8% (16/77) of the patients had positive anti-DNA. Low C3 complement was observed in 30/77 (39%) and low C4 in 50/77 (64.9%) patients.
Patients were grouped based on RA disease duration (0-2, 3-5, 6-10 and >10 years from diagnosis). Unadjusted prevalence erosion rates were calculated based on the proportion of patients with reports of erosions present on joint radiographs/MRIs/ultrasounds. Seropositivity was based on laboratory results (anti-CCP ≥20 U/mL) at enrolment in the Corrona registry. Chi-squared tests were used to assess differences in prevalence rates. Results: There were 9759 patients who met inclusion criteria. Most were women (76%), middle-aged (mean [SD] 57 years [14]), with moderate disease activity (mean [SD] CDAI 14.7 [13.4] ). Prior use of at least one biologic or targeted synthetic DMARD had occurred in 41% of patients. Overall, the prevalence of erosive disease was 28.6%, with higher prevalence among CCP+ (35.4%) vs CCP-(20.1%) patients (p<0.001, chi-squared test). The prevalence of erosions increased with increasing disease duration (p<0.001; Table) . For each disease duration group, the prevalence of erosions was higher in patients who were CCP+ compared with those who were CCP−. 
